Stocks and Investing
Stocks and Investing
Fri, January 15, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Geoff Meacham Downgraded (YMAB) to Hold and Held Target at $56 on, Jan 15th, 2021
Geoff Meacham of B of A Securities, Downgraded "Y-mAbs Therapeutics, Inc." (YMAB) to Hold and Held Target at $56 on, Jan 15th, 2021.
Geoff has made no other calls on YMAB in the last 4 months.
There is 1 other peer that has a rating on YMAB. Out of the 1 peers that are also analyzing YMAB, 0 agree with Geoff's Rating of Hold.
This is the rating of the analyst that currently disagrees with Geoff
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $65 on, Monday, November 9th, 2020
Contributing Sources